A multiple-ascending-dose study to evaluate the efficacy, safety, and pharmacokinetics (PK) of MEDI0382 in overweight and obese participants with Type 2 Diabetes Mellitus

Exclusion Criteria

• -Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product
• -History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
• -History of cancer within the last 10 years, with the exception of non-melanoma skin cancer
• -Any clinically important illness (except for T2DM), medical/surgical procedure, or trauma within 4 weeks prior to dosing
• -Fasting glucose greater than or equal to (>=) 200 mg/dL
• -Positive Hepatitis B, Hepatitis C or human immunodeficiency virus test or use of antiretroviral medications at screening.
• -Concurrent or previous use of a glucagon-like peptide 1 receptor agonist
• -Current or previous use of systemic corticosteroids within the past 28 days prior to screening
• -Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited.
• -Known or suspected history of alcohol or drug abuse within the past 3 years.
• -Positive drug screen